Lipoprotein particle alterations due to androgen therapy in individuals with dyskeratosis congenita
Sign Up to like & getrecommendations! Published in 2021 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2021.103760
Abstract: Summary Background Dyskeratosis congenita (DC) is a telomere biology disorder associated with high rates of bone marrow failure (BMF) and other medical complications. Oral androgens are successfully used to treat BMF in DC but often… read more here.
Keywords: androgen therapy; dyskeratosis congenita; lipoprotein particle; androgen ... See more keywords
Molecular determinants of response to high dose androgen therapy in prostate cancer.
Sign Up to like & getrecommendations! Published in 2019 at "JCI insight"
DOI: 10.1172/jci.insight.129715
Abstract: Clinical trials of high-dose androgen therapy for prostate cancer have shown promising efficacy but are limited by lack of criteria to identify likely responders. To elucidate factors that govern the growth-repressive effects of high-dose androgens… read more here.
Keywords: androgen; high dose; dose androgen; prostate cancer ... See more keywords
Androgen Therapy for Lower-Risk Myelodysplastic Syndrome
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-115931
Abstract: Background Improvement of cytopenia is one of the primary treatment purposes for patients with the lower-risk myelodysplastic syndrome (MDS). Androgens have been used for the treatment of aplastic anemia, immune thrombocytopenia, and telomere diseases. In… read more here.
Keywords: androgen therapy; risk; treatment; lower risk ... See more keywords
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5517
Abstract: 5517Background: Rapid cycling between high and low testosterone (T) (i.e BAT) produces tumor response in mCRPC, and may overcome resistance to newer AR therapies. Here we report a randomized study ... read more here.
Keywords: mcrpc; bat; therapy bat; androgen therapy ... See more keywords
Androgen Therapy in Neurodegenerative Diseases
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvaa120
Abstract: Abstract Neurodegenerative diseases, including Alzheimer disease (AD), Parkinson disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Huntington disease, are characterized by the loss of neurons as well as neuronal function in multiple regions… read more here.
Keywords: therapy neurodegenerative; disease; neurodegenerative diseases; androgen therapy ... See more keywords
Selective androgen receptor modulators: the future of androgen therapy?
Sign Up to like & getrecommendations! Published in 2020 at "Translational andrology and urology"
DOI: 10.21037/tau.2019.11.02
Abstract: Selective androgen receptor modulators (SARMs) are small molecule drugs that function as either androgen receptor (AR) agonists or antagonists. Variability in AR regulatory proteins in target tissues permits SARMs to selectively elicit anabolic benefits while… read more here.
Keywords: androgen; selective androgen; receptor modulators; androgen therapy ... See more keywords
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres
Sign Up to like & getrecommendations! Published in 2022 at "ecancermedicalscience"
DOI: 10.3332/ecancer.2022.1480
Abstract: Background Previous studies with bipolar androgen therapy (BAT) have shown clinical activity in metastatic Castration Resistant Prostate Cancer (mCRPC) as well as the potential to re-sensitise prostate cancer cells to prior androgen receptor-targeted agents. None… read more here.
Keywords: oncology; androgen therapy; bat; treatment ... See more keywords